Abstract
BackgroundWe report a rare case of malignant phyllodes tumors (MPT) with partial response to apatinib.Case presentationA 26-year-old woman had a palpable mass in her right breast for over a year. After resection, pathology indicated malignant phyllodes tumor. Eleven months after surgery, she underwent reoperation for a lung nodule, which demonstrated lung metastasis. She refused chemotherapy and was rehospitalized six months later due to leg pain. Pelvic mass biopsy revealed metastatic malignant phyllodes tumor. After concurrent chemoradiotherapy of the pelvic mass, multiple lung metastases emerged. Subsequent treatment with apatinib 500 mg/day resulted in a reduction in mass size and partial response. She survived for more than 8 months.ConclusionThe present case showed the potential therapeutic effects of apatinib in patients with MPT.
Highlights
We report a rare case of malignant phyllodes tumors (MPT) with partial response to apatinib.Case presentation: A 26-year-old woman had a palpable mass in her right breast for over a year
Malignant phyllodes tumors (MPT) have a poor prognosis, with most patients dying within 3 years after starting treatments [1]
We present a case of metastatic MPT of the breast that was effectively treated with apatinib
Summary
We report a rare case of malignant phyllodes tumors (MPT) with partial response to apatinib.Case presentation: A 26-year-old woman had a palpable mass in her right breast for over a year. Conclusion: The present case showed the potential therapeutic effects of apatinib in patients with MPT. Malignant phyllodes tumors (MPT) have a poor prognosis, with most patients dying within 3 years after starting treatments [1]. Co., Ltd., Shanghai, China) is a small-molecule tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor 2 (VEGFR-2) and has been proven to be effective and safe for multiple solid tumors [5].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
